OncoMatch/Clinical Trials/NCT06439771
A Phase 2 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of YL202 in Patients With BC
Is NCT06439771 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies YL202 should be intravenously infused for locally advanced or metastatic breast cancer.
Treatment: YL202 should be intravenously infused — This study is a multicenter, open-label, phase 2 clinical study to evaluate the efficacy, safety and pharmacokinetics of YL202 in patients with locally advanced or metastatic breast cancer with TNBC, HR-positive, HER2-zero-expression or HER2-low-expression
Check if I qualifyExtracted eligibility criteria
Cancer type
Breast Carcinoma
Biomarker criteria
Required: ESR1 HR-negative
HR-negative
Required: HER2 (ERBB2) HER2-negative
HER2-negative
Required: ESR1 HR-positive
HR positive
Required: HER2 (ERBB2) HER2-Zero-expression
HER2-Zero-expression
Required: HER2 (ERBB2) HER2-Low-expression
HER2-Low-expression
Disease stage
Required: Stage III, IV
Prior therapy
Must have received: antibody-drug conjugate (HER2-ADC, TROP2-ADC)
previously failed treatments of HER2-ADC or TROP2-ADC
Cannot have received: HER3-targeted therapy
prior treatment with an agent targeting HER3
Cannot have received: topoisomerase I inhibitor
prior intolerance to treatment with topoisomerase I inhibitor or an ADC that consists of topoisomerase I inhibitor
Lab requirements
Blood counts
adequate organ and bone marrow function within 7 days prior to the first dose
Kidney function
Liver function
Have Adequate organ and bone marrow function within 7 days prior to the first dose.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify